vs

Side-by-side financial comparison of Super League Enterprise, Inc. (SLE) and TScan Therapeutics, Inc. (TCRX). Click either name above to swap in a different company.

Super League Enterprise, Inc. is the larger business by last-quarter revenue ($3.2M vs $2.6M, roughly 1.2× TScan Therapeutics, Inc.). Super League Enterprise, Inc. runs the higher net margin — -316.9% vs -895.1%, a 578.2% gap on every dollar of revenue. On growth, TScan Therapeutics, Inc. posted the faster year-over-year revenue change (286.0% vs -6.6%). Over the past eight quarters, TScan Therapeutics, Inc.'s revenue compounded faster (-9.7% CAGR vs -12.8%).

Super League Enterprise, Inc. is a global gaming and esports entertainment firm that creates interactive live events, original content, and community experiences for casual and core gaming audiences. It runs competitive gaming leagues, brand partnership activations, and digital media platforms, serving North America, Europe, and key Asia-Pacific markets.

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel T cell receptor (TCR) immunotherapies for hard-to-treat cancers. Its proprietary platform identifies high-affinity naturally occurring TCRs targeting tumor antigens, with pipeline candidates spanning hematological malignancies and solid tumors, operating in the global oncology therapeutics market.

SLE vs TCRX — Head-to-Head

Bigger by revenue
SLE
SLE
1.2× larger
SLE
$3.2M
$2.6M
TCRX
Growing faster (revenue YoY)
TCRX
TCRX
+292.6% gap
TCRX
286.0%
-6.6%
SLE
Higher net margin
SLE
SLE
578.2% more per $
SLE
-316.9%
-895.1%
TCRX
Faster 2-yr revenue CAGR
TCRX
TCRX
Annualised
TCRX
-9.7%
-12.8%
SLE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
SLE
SLE
TCRX
TCRX
Revenue
$3.2M
$2.6M
Net Profit
$-10.1M
$-23.0M
Gross Margin
31.5%
Operating Margin
-100.8%
-929.4%
Net Margin
-316.9%
-895.1%
Revenue YoY
-6.6%
286.0%
Net Profit YoY
-91.8%
35.8%
EPS (diluted)
$-0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
SLE
SLE
TCRX
TCRX
Q4 25
$3.2M
$2.6M
Q3 25
$2.4M
$2.5M
Q2 25
$3.0M
$3.1M
Q1 25
$2.7M
$2.2M
Q4 24
$3.4M
Q3 24
$4.4M
$1.0M
Q2 24
$4.1M
Q1 24
$4.2M
Net Profit
SLE
SLE
TCRX
TCRX
Q4 25
$-10.1M
$-23.0M
Q3 25
$-3.6M
$-35.7M
Q2 25
$-2.8M
$-37.0M
Q1 25
$-4.2M
$-34.1M
Q4 24
$-5.3M
Q3 24
$-3.6M
$-29.9M
Q2 24
$-2.5M
Q1 24
$-5.3M
Gross Margin
SLE
SLE
TCRX
TCRX
Q4 25
31.5%
Q3 25
44.6%
Q2 25
43.6%
Q1 25
44.0%
Q4 24
29.2%
Q3 24
38.9%
Q2 24
40.0%
Q1 24
41.1%
Operating Margin
SLE
SLE
TCRX
TCRX
Q4 25
-100.8%
-929.4%
Q3 25
-125.9%
-1475.6%
Q2 25
-104.8%
-1256.6%
Q1 25
-133.6%
-1669.7%
Q4 24
-134.4%
Q3 24
-77.9%
-3109.8%
Q2 24
-99.4%
Q1 24
-109.4%
Net Margin
SLE
SLE
TCRX
TCRX
Q4 25
-316.9%
-895.1%
Q3 25
-147.0%
-1422.1%
Q2 25
-92.7%
-1201.3%
Q1 25
-155.6%
-1571.9%
Q4 24
-154.3%
Q3 24
-82.0%
-2849.1%
Q2 24
-59.6%
Q1 24
-125.0%
EPS (diluted)
SLE
SLE
TCRX
TCRX
Q4 25
$-0.18
Q3 25
$-2.65
$-0.28
Q2 25
$-0.28
Q1 25
$-0.26
Q4 24
Q3 24
$-21.47
$-0.25
Q2 24
Q1 24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
SLE
SLE
TCRX
TCRX
Cash + ST InvestmentsLiquidity on hand
$14.4M
$152.4M
Total DebtLower is stronger
$32.5M
Stockholders' EquityBook value
$17.5M
$123.1M
Total Assets
$21.9M
$228.8M
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
SLE
SLE
TCRX
TCRX
Q4 25
$14.4M
$152.4M
Q3 25
$1.1M
$184.5M
Q2 25
$475.0K
$218.0M
Q1 25
$747.0K
$251.7M
Q4 24
$1.3M
Q3 24
$289.0K
$271.1M
Q2 24
$1.7M
Q1 24
$3.3M
Total Debt
SLE
SLE
TCRX
TCRX
Q4 25
$32.5M
Q3 25
$32.4M
Q2 25
$32.3M
Q1 25
$32.2M
Q4 24
Q3 24
$30.6M
Q2 24
Q1 24
Stockholders' Equity
SLE
SLE
TCRX
TCRX
Q4 25
$17.5M
$123.1M
Q3 25
$-2.0M
$144.0M
Q2 25
$-4.1M
$176.7M
Q1 25
$-3.5M
$210.2M
Q4 24
$170.0K
Q3 24
$3.5M
$229.1M
Q2 24
$5.1M
Q1 24
$6.0M
Total Assets
SLE
SLE
TCRX
TCRX
Q4 25
$21.9M
$228.8M
Q3 25
$8.7M
$262.2M
Q2 25
$8.5M
$298.6M
Q1 25
$9.8M
$332.7M
Q4 24
$11.7M
Q3 24
$12.6M
$348.0M
Q2 24
$15.4M
Q1 24
$18.6M
Debt / Equity
SLE
SLE
TCRX
TCRX
Q4 25
0.26×
Q3 25
0.23×
Q2 25
0.18×
Q1 25
0.15×
Q4 24
Q3 24
0.13×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
SLE
SLE
TCRX
TCRX
Operating Cash FlowLast quarter
$-3.9M
$-32.0M
Free Cash FlowOCF − Capex
$-32.2M
FCF MarginFCF / Revenue
-1253.3%
Capex IntensityCapex / Revenue
6.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-139.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
SLE
SLE
TCRX
TCRX
Q4 25
$-3.9M
$-32.0M
Q3 25
$-2.8M
$-32.5M
Q2 25
$-1.8M
$-33.3M
Q1 25
$-2.2M
$-37.6M
Q4 24
$-3.3M
Q3 24
$-2.1M
$-27.9M
Q2 24
$-2.3M
Q1 24
$-3.7M
Free Cash Flow
SLE
SLE
TCRX
TCRX
Q4 25
$-32.2M
Q3 25
$-33.9M
Q2 25
$-34.5M
Q1 25
$-39.1M
Q4 24
Q3 24
$-2.1M
$-29.3M
Q2 24
Q1 24
FCF Margin
SLE
SLE
TCRX
TCRX
Q4 25
-1253.3%
Q3 25
-1349.6%
Q2 25
-1123.1%
Q1 25
-1801.8%
Q4 24
Q3 24
-48.1%
-2792.0%
Q2 24
Q1 24
Capex Intensity
SLE
SLE
TCRX
TCRX
Q4 25
6.7%
Q3 25
56.8%
Q2 25
41.6%
Q1 25
70.6%
Q4 24
0.0%
Q3 24
0.5%
130.6%
Q2 24
0.0%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

SLE
SLE

Advertising And Sponsorships$1.8M57%
Publishing And Content Studio$1.4M43%

TCRX
TCRX

Segment breakdown not available.

Related Comparisons